Concepedia

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Díaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James J. Sims, Giovanni Di Perri,

The Lancet HIV · 2023 · 115 citations · 22 references

DOI

Concepts

References

22

World Medical Association Declaration of Helsinki

JAMA · 2013 · 29.4K citations

, , +2

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

, , +17

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Michael S. Saag, Rajesh T. Gandhi, Jennifer Hoy et al. · JAMA · 2020 · 467 citations · Full text

, , +17

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 464 citations · Full text

, , +14

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations

, , +15